Background: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. 
Introduction
Ulcerative colitis [UC] is an idiopathic chronic inflammatory disorder that affects the innermost lining or mucosa of the colon and rectum, and patients suffer from uncomfortable symptoms such as diarrhoea, rectal bleeding, and abdominal pain. The clinical course of UC is characterised by repetitive cycles of relapses and remissions, and clinical relapse can largely hinder the patient's quality of life. Therefore, if clinical relapse could be predicted beforehand in UC patients in clinical remission, optimising treatment could obviate the incidence of relapse.
Recently, endoscopic mucosal healing [MH] is being pursued as a treatment goal for UC alongside clinical remission, because patients with MH have been shown to have a reduced risk of relapse. 1 In this regard, achieving MH is a strong predictor for a lower risk of relapse. Therefore, evaluating the colonic mucosa of patients in clinical remission appears to be a reasonable approach regarding the prediction of the prognosis. However, a major disadvantage of using the mucosal status is that it requires a colonoscopy, which is an invasive and costly procedure. Thus, faecal surrogate markers for the mucosal status of UC have been evaluated.
Several studies have shown that faecal calprotectin [Fcal] can be a surrogate marker for colonoscopy and that its value reflects the mucosal status of UC.
2,3 Meanwhile, we have reported the usefulness of the faecal immunochemical test [FIT] as a surrogate marker of UC, and the performance of FIT for predicting MH was equivalent or superior to that of Fcal. [4] [5] [6] In addition, both faecal markers have been reported to be useful in predicting clinical relapse of patients with UC. [6] [7] [8] [9] [10] [11] [12] [13] [14] However, the difference between Fcal and FIT in the performance of predicting relapse has scarcely been reported. Furthermore, it is largely unknown whether the combined use of these faecal markers increases the predictability of the prognosis of UC patients.
In this study, we examined Fcal and FIT in UC patients in clinical remission and observed their clinical course in a prospective manner. The difference in the predictability of relapse between these two markers and the synergistic effect on the prediction of relapse were evaluated.
Materials and Methods

Patients and study design
A multicentre prospective observational study was performed. Between January 2014 and January 2015, UC patients in clinical remission for at least 3 months were consecutively enrolled at Okayama University Hospital, Kagawa Prefectural Central Hospital, and Hiroshima City Hiroshima Citizens Hospital. All three hospitals are tertiary centres for inflammatory bowel disease in the western region of Japan. The diagnosis of UC was based on typical endoscopic and histological assessments. Clinical disease activity was evaluated by the using the Mayo score [scoring system for assessment of UC activity], and clinical remission was defined as a partial Mayo score [Mayo score without endoscopic findings] ≤ 2 points, with no individual subscore exceeding 1 point. 15 Patients who refused to enrol in this study were excluded.
At enrolment, patients underwent colonoscopy and submitted two faecal samples to measure Fcal and FIT. The mucosal status observed during the colonoscopy was assessed using the Mayo Endoscopic Subscore [MES] classification system. An evaluation of each region of the colorectum [caecum, ascending, transverse, descending, and sigmoid colon, and rectum] was performed, and the maximum score in the colorectum of each patient was noted. All stool samples were collected on the day or a few days preceding the colonoscopy, before starting the preparation for colonoscopy.
Patients were followed with approximately bimonthly visit intervals for either 2 years after enrolment or until relapse. The primary endpoint was the incidence of clinical relapse during the follow-up period according to the measured Fcal and/or FIT values at enrolment. Clinical relapse was defined as a partial Mayo score ≥ 3 points with an addition or modification of medications. Changes in medications during sustained clinical remission [eg tapering of corticosteroids and tacrolimus] were made at the discretion of each attending physician. This study was approved by the institutional review board at each institution. Informed consent was obtained from each patient. There were no conflicts of interest or sponsors in this study.
Faecal calprotectin analysis
Faecal samples, which were submitted by the patients for calprotectin analysis, were stored at -70°C until shipment to the laboratory. The samples were sent to the Institute of Applied Technology for Innate Immunity [Kagawa, Japan]. Calprotectin was measured in stool samples using a PhiCal® Calprotectin ELISA kit [Immundiagnostik AG, Germany]. The quantitative range was between 0.65 µg/g and 84 000 µg/g for calprotectin, after an appropriate dilution of the faecal samples from 1:50 to 1:100 000.
Faecal immunochemical test analysis
Details of the method used for FIT have been described previously. In brief, patients collected faecal samples using an OC-Hemodia® sampling probe [Eiken Chemical, Tokyo, Japan]. The stool samples were immediately processed and examined using OC-SENSOR DIANA [Eiken Chemical], which can accurately measure faecal haemoglobin concentrations between 50 ng/mL and 1000 ng/mL. Faecal specimens with a haemoglobin concentration over 1000 ng/mL were retested after dilution. On the other hand, faecal specimens with a haemoglobin concentration lower than 50 ng/mL were categorised as one [0-50 ng/mL].
Statistical analysis
Statistical analysis was conducted using the JMP program [version 9, SAS Institute, Cary, NC, USA]. Receiver operating characteristic curves were constructed to define a cutoff value for the Fcal and FIT levels, and the area under the curve [AUC] was calculated to indicate the sensitivity and specificity of the Fcal and FIT in predicting clinical relapse. A Cox proportional hazards regression model was used to calculate hazard ratios [HRs] with 95% confidence intervals [CIs] for the risk of relapse. The cumulative percentage of relapse-free patients was determined using Kaplan-Meier analysis and compared using the log-rank test. A power analysis was performed using a PS power and sample size calculator [http://biostat.mc.vanderbilt.edu/PowerSampleSize]. In our retrospective cohort study, the clinical relapse rates were 67% [55/82] in FIT-positive and 18% [20/112] in FIT-negative subjects. 13 Based on the results of the previous study, we hypothesised a 2-fold difference in the probability of relative risk of clinical relapse between FIT-positive and FIT-negative subjects, and calculated a sample size with 80% power and 0.05 probability level. All p-values were two-sided and considered significant when they were less than 0.05.
Results
Clinical characteristics of the patients
A total of 116 UC patients in clinical remission underwent colonoscopy and submitted two faecal samples to measure Fcal and FIT.
Of these, three patients were excluded because of loss of follow-up [ Figure 1 ]. The final study population consisted of 113 patients. 
Predictors of clinical relapse of UC
Receiver operating characteristic curves showed that the optimal cutoff levels for Fcal and FIT were 75 μg/g and 110 ng/mL, respectively. Therefore, Fcal ≥ 75 μg/g and FIT ≥ 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively. The sensitivity, specificity, and AUC of Fcal, FIT, and the combination of Fcal and FIT, for predicting relapse are shown in Table 2 Kaplan-Meier curves comparing the maintenance of clinical remission according to the status of faecal markers at enrolment are shown [ Figure 2 ]. Both Fcal-positive [ Figure 2A ] and FIT-positive [ Figure 2B ] patients showed a higher cumulative relapse rate than those of each counterpart [p = 0.0016, and p < 0.0001, respectively, log-rank test]. In comparing Fcal-positive and FIT-positive patients, the 1-year and 2-year relapse rates were higher in the FIT-positive group than in the Fcal-positive group [50% vs 29%, and 68% vs 50%, respectively].
To stratify patients more precisely regarding the prognosis, FITnegative patients were further divided into two groups according to Fcal status. Consequently, patients were classified into three groups: FIT-positive, FIT-negative and Fcal-positive, and both negative. An increase in the risk of relapse was observed in the FIT-negative and Fcal-positive [HR 2.05; 95% CI, 1.02-4.43; p = 0.0045] and the FIT-positive [HR 5.43; 95% CI, 2.57-11.76; p < 0.0001] groups compared with the both negative group [ Table 4 ]. The cumulative remission maintenance rates significantly differed among the three groups [p < 0.0001, log-rank test] [ Figure 3 ]. According to the Kaplan-Meier analysis, FIT-positive patients were more susceptible to early relapse [1-year relapse rate: 50%], whereas FIT-negative patients were more likely to be in clinical remission within 1 year regardless of the Fcal-negative or Fcal-positive status [6-month relapse rate: 9% vs 10%, 1-year relapse rate: 16% vs 18%, respectively]. However, a difference in the relapse rate emerged later [2-year relapse rates; FIT-negative and Fcal-positive: 40% vs both negative: 22%] [ Figure 3 ]. These results suggest that FIT positivity reflects a different clinical property from Fcal positivity, and that the risk of relapse in UC patients in clinical remission could be stratified more efficiently by using both faecal markers.
Discussion
Fcal is an effective surrogate marker that reflects mucosal status in UC. 2, 3, 5, [16] [17] [18] [19] [20] [21] Moreover, several studies have reported that Fcal is useful for predicting clinical relapse in UC. [7] [8] [9] [10] [11] [12] Tibble et al. reported that elevated calprotectin levels [cutoff level: 50 mg/L] showed a good predictive value for clinical relapse during the following 12-month period. 7 Costa et al. demonstrated a 14-fold greater risk of relapse in UC patients if the calprotectin levels were greater than 150 µg/g.
11
Other studies have also shown that patients with elevated calprotectin values are at risk of relapse within 3 to 6 months. 10, 12 On the other hand, we have reported the usefulness of FIT in UC. using an antibody specific for human haemoglobin, and this test has proven to be an available non-invasive test for screening colorectal neoplasia. 22 In UC, FIT predicted MH [defined as MES 0 alone] with 92% sensitivity and 71% specificity. 4 Our previous report indicated that the sensitivity of FIT for MES 0 alone was more than 10 points higher than that of Fcal. 5 Regarding the prediction of clinical relapse, UC patients in clinical remission with a FIT-negative status had a 6-fold lower risk of clinical relapse than patients who were FITpositive. 13 Thus, although both Fcal and FIT are useful in predicting clinical relapse, the difference in the performance of these markers in predicting relapse has not previously been evaluated.
In the era of MH, it may be an optimal treatment strategy for all UC patients in clinical remission to aim for MH. In real clinical practice, however, such a strategy is hardly achievable because colonoscopy for patients in clinical remission appears to be an excessive burden. In this regard, the role of biomarkers to predict MH is highly relevant. Previous reports have indicated that both faecal markers─Fcal and FIT─reflect endoscopic mucosal inflammation and MH and can predict prognosis, particularly clinical relapse. Therefore, patients in clinical remission might be monitored using faecal markers to prevent relapse without requiring colonoscopy. For this purpose, maximising the predictability of relapse with these two markers is warranted.
In this study, we enrolled UC patients in clinical remission, measured Fcal and FIT, and evaluated the difference in the predictive performance of these two faecal markers. Consequently, Fcal and FIT proved to have distinct properties regarding the prediction of relapse, both functioning as independent predictors of clinical relapse in UC patients in clinical remission. Furthermore, we confirmed that categorisation of UC patients in clinical remission into three groups according to combined status of the two markers FITpositive, FIT-negative and Fcal-positive, and both negative, could increase the ability to predict relapse. Thus, using both faecal markers in UC patients in clinical remission appears to have a synergistic effect on predicting relapse and could allow physicians to provide optimal maintenance therapies without the use of colonoscopy.
In the present study, FIT-positive patients were susceptible to early relapse [1-year relapse rate: 50%] compared with Fcal-positive 13, [23] [24] [25] In our previous study, patients with MES ≥ 1 had a higher relapse rate than those with MES 0 [MES 0, 13%; MES 1, 53%; and MES 2, 74%,;median follow-up period 17 months]. 13 Thus, the fact that FIT-positive patients were more likely to have elevated endoscopic activity than Fcal-positive patients largely contributed to the difference in prediction between these two markers.
With regard to the incidence of relapse, FIT-negative patients could be classified into one of two groups according to the Fcal status. Among the 44 FIT-negative and Fcal-positive patients, MES 0 was observed in 22 [50%] . On the other hand, among the 50 both negative patients, MES 0 was observed in 39 [78%]. Thus, the difference in prognosis between FIT-negative and Fcal-positive patients and both negative patients could also be attributed to the difference in endoscopic activity. Measurements of the two faecal markers with different properties increased the predictability of complete MH [MES 0 alone] compared with measuring either parameter alone, and this fact appears to contribute to the increase in predictability of relapse by using two faecal markers.
In addition, the prognostic difference among FIT-negative subjects according to the Fcal status may be accountable referring to histological aspects. According to recent studies, achieving both endoscopic and histological remission was associated with better long-term outcomes compared with achieving endoscopic remission alone. [26] [27] [28] In this context, Fcal may be more sensitive to slight histological inflammation than FIT because the former reflects the presence of inflammatory cells in the mucosa, whereas the latter is dependent on mucosal bleeding. The difference in the relapse rate between FIT-negative and Fcal-positive patients and both negative patients became obvious more than 1 year after enrolment. Earlier relapse in patients with clinical remission appears to be dependent on endoscopic activity, and relapse in later years in patients with endoscopic remission could be associated with minimal histological activity. Because histology was not examined in every patient in this study, this hypothesis should be validated in the future.
In the current study, we have shown that monitoring UC patients in clinical remission using both faecal markers is the best strategy. In real clinical practice, however, optimally selecting between the two markers depending on the situation is expected because of cost. FIT has a much lower cost than Fcal [approximately $22 vs $180, respectively]; thus, the use of Fcal analysis should be minimised, and the use of FIT should be maximised. On the basis of our results and the cost-effectiveness of these markers, we propose the following protocol for the clinical management of UC patients in clinical remission using faecal markers. When UC patients enter clinical remission, FIT should be measured first. Patients with a positive FIT result would require meticulous follow-up or adjustment of medication because they are considered to have residual inflammation and are at considerable risk of relapse. In cases with a negative FIT result, patients should be monitored by periodic measurements of Fcal at least once a year, due to the difference in relapse rate after a 1-year follow-up according to the Fcal status.
There are limitations to this study. Although this study was designed in a prospective manner, the clinical course of the enrolled patients might be influenced by remission maintenance therapy, which was implemented by different attending physicians at the hospitals included in this study. However, all the physicians who participated in this study were inflammatory bowel disease specialists, and they administered the best treatment based on the same guidelines. In addition, the higher relapse rate in this study might affect the results, because our cohort included patients with considerable endoscopic inflammation [eg MES 2] . In this context, we also performed similar analyses for patients with MH [MES 0 or 1], but the results did not differ largely from those from the whole cohort, except for the marginal relapse risk difference between FIT-negative and Fcal-positive patients vs both negative patients [Supplementary Tables 3 and 4 , available as Supplementary data at ECCO-JCC online]. Moreover, inclusion of patients receiving corticosteroids or tacrolimus might yield additional bias, because those subjects might be likely to flare during the period with tapering of the agents. In this regard, we performed sensitivity analysis with exclusion of those subjects, and confirmed that the results did not differ significantly from the analysis for full subjects [Supplementary Table 5 , available as Supplementary data at ECCO-JCC online]. The lack of colonoscopy at relapse may also be a drawback, but a particular strength of this study was the presence of endoscopic findings upon enrolment. Histological findings in patients entering clinical remission might have strengthened the conclusions made from the data. Last, a single measurement for each faecal test may be somewhat inaccurate, and consecutive measurements might minimise the intra-patient variability. In conclusion, our study revealed that both FIT and Fcal effectively predicted clinical relapse in UC patients in clinical remission. Moreover, Fcal vs FIT showed distinct properties regarding relapse prediction in UC, and a risk assessment using both faecal markers could increase the predictability of relapse. Optimal use of these two faecal markers would provide a better prognosis for UC patients.
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